A Study to Investigate Interleukin-6 (IL-6) and IL-6/Soluble IL-6 Receptor (sIL-6R) Complex Levels in Subjects With Active Inflammatory Bowel Disease

Inclusion Criteria: * Subjects diagnosed with active moderate to severe ulcerative colitis (\*partial Mayo ≥ 5) or Crohn's disease (Harvey \& Bradshaw ≥ 8) \*partial Mayo: 9-point scale that excludes the endoscopic components of the Mayo score Exclusion Criteria: * Presence of another inflammatory disease, except for mild cutaneous psoriasis * Concomitant gastrointestinal infection or otherwise serious infection including Crohn's disease infectious complication * Treatment with Infliximab, Adalimumab, Certolizumab Pegol or other immune-modulating biologics within 8 weeks prior to the visit * Having a known or suspected gastrointestinal or otherwise serious infection within 8 weeks prior to the visit * Concomitant diagnosed or suspected malignant disease